Background
Methods
Patient eligibility and variables
Statistical methods
Results
Baseline characteristics
Variables | Training cohort | Validation cohort | Test cohort | |||
---|---|---|---|---|---|---|
(n = 27700) | (n = 3158) | (n = 25214) | ||||
Sex, n, % | ||||||
Female | 14077 | 50.8 | 1605 | 50.8 | 12702 | 50.4 |
Male | 13623 | 49.2 | 1553 | 49.2 | 12512 | 49.6 |
Age, year, median, range | 67 | 18–99 | 67 | 18–99 | 67 | 18–99 |
Race, n, % | ||||||
White | 21722 | 78.4 | 2428 | 76.9 | 19710 | 78.2 |
Black | 3422 | 12.4 | 412 | 13.0 | 3106 | 12.3 |
Yellow (Chinese, Korean and Japanese) | 1229 | 4.4 | 169 | 5.4 | 1075 | 4.3 |
Other | 1327 | 4.8 | 149 | 4.7 | 1323 | 5.2 |
Marital status at diagnosis, n, % | ||||||
Married (including separated) | 15900 | 57.4 | 1812 | 57.3 | 14166 | 56.2 |
Divorced | 2378 | 8.6 | 266 | 8.4 | 2297 | 9.1 |
Single (never married) | 3519 | 12.7 | 406 | 12.9 | 3553 | 14.1 |
Widowed | 5185 | 18.7 | 601 | 19.1 | 4363 | 17.3 |
Unknown | 718 | 2.6 | 73 | 2.3 | 835 | 3.3 |
CEA status, n, % | ||||||
Negative | 15550 | 56.1 | 1803 | 57.1 | 14824 | 58.8 |
Positive | 12150 | 43.9 | 1355 | 42.9 | 10390 | 41.2 |
Tumor site, n, % | ||||||
Proximal colon (cecum to splenic flexure) | 14341 | 51.7 | 1621 | 51.3 | 13790 | 54.7 |
Distal colon (descending to sigmoid colon) | 8015 | 29.0 | 952 | 30.2 | 7441 | 29.5 |
Overlapping lesion of colon | 284 | 1.0 | 24 | 0.8 | 275 | 1.1 |
Rectum (including rectosigmoid junction) | 5060 | 18.3 | 561 | 17.7 | 3708 | 14.7 |
Tumor size, n, % | ||||||
≤ 5 cm | 16861 | 60.9 | 1966 | 62.3 | 15178 | 60.2 |
> 5 cm | 9120 | 32.9 | 998 | 31.6 | 8557 | 33.9 |
Unknown | 1719 | 6.2 | 194 | 6.1 | 1479 | 5.9 |
Extent of surgery, n, % | ||||||
Local/segmental resection | 12879 | 46.5 | 1505 | 47.7 | 11464 | 45.5 |
Subtotal/hemisection | 13991 | 50.5 | 1549 | 49.0 | 13137 | 52.1 |
Total resection | 830 | 3.0 | 104 | 3.3 | 613 | 2.4 |
Histology, n, % | ||||||
Adenocarcinoma | 27375 | 98.8 | 3116 | 98.7 | 24975 | 99.1 |
Signet ring cell carcinoma | 325 | 1.2 | 42 | 1.3 | 239 | 0.9 |
Tumor grade, n, % | ||||||
Well to Moderately differentiated (G1 + G2) | 21137 | 76.3 | 2435 | 77.1 | 19450 | 77.2 |
Poorly to Undifferentiated (G3 + G4) | 5931 | 21.4 | 646 | 20.5 | 5202 | 20.6 |
Unknown | 632 | 2.3 | 77 | 2.4 | 562 | 2.2 |
pT stage, n, % | ||||||
pT1 | 2381 | 8.6 | 272 | 8.6 | 2662 | 10.6 |
pT2 | 3987 | 14.4 | 447 | 14.2 | 3844 | 15.2 |
pT3 | 17094 | 61.7 | 1980 | 62.7 | 14887 | 59.0 |
pT4a | 2244 | 8.1 | 256 | 8.1 | 2242 | 8.9 |
pT4b | 1994 | 7.2 | 203 | 6.4 | 1579 | 6.3 |
pN stage, n, % | ||||||
N0 | 14069 | 50.8 | 1615 | 51.1 | 13378 | 53.1 |
N1a | 3445 | 12.4 | 402 | 12.7 | 3005 | 11.9 |
N1b | 3960 | 14.3 | 456 | 14.4 | 3378 | 13.4 |
N2a | 3055 | 11.0 | 356 | 11.2 | 2611 | 10.4 |
N2b | 3171 | 11.5 | 329 | 10.4 | 2842 | 11.2 |
Lymph node count, mean, sd | 15.7 | 9.6 | 15.8 | 9.6 | 18.4 | 9.6 |
Lymph node ratio, mean, IQR | 0.16 | 0–0.24 | 0.16 | 0–0.22 | 0.13 | 0–0.18 |
Metastasis, n, % | ||||||
M0 | 22512 | 81.3 | 2587 | 81.9 | 21112 | 83.7 |
M1 | 5188 | 18.7 | 571 | 18.1 | 4102 | 16.3 |
Follow-up | 63 | 1–107 | 64 | 1–107 | 34 | 1–59 |
Number of events | 9341 | 13359 | 1055 | 1496 | 5659 | 7689 |
1-year cumulative survival | 87.9 | 84.1 | 88.6 | 84.7 | 89.8 | 86.5 |
3-year cumulative survival | 73.8 | 67.1 | 75.1 | 68.7 | 77.3 | 70.9 |
5-year cumulative survival a | 66.6 | 57.2 | 67.7 | 58.6 | 70.8 | 60.6 |
Cox regression of training cohort
Variables | Cancer-specific survival | Overall survival | ||||
---|---|---|---|---|---|---|
HR | 95 % CI |
P
| HR | 95 % CI |
P
| |
Sex | ||||||
Female | ref | ref | ||||
Male | 1.060 | 1.018–1.104 | 0.0049 | 1.055 | 1.019–1.091 | 0.0021 |
Race | ||||||
White | ref | ref | ||||
Black | 1.278 | 1.206–1.354 | <0.0001 | 1.157 | 1.101–1.216 | <0.0001 |
Yellow (Chinese, Korean and Japanese) | 0.762 | 0.682–0.850 | <0.0001 | 0.701 | 0.638–0.770 | <0.0001 |
Other | 0.974 | 0.884–1.072 | 0.5850 | 0.870 | 0.800–0.946 | 0.0011 |
Marital status at diagnosis | ||||||
Married (including separated) | ref | ref | ||||
Divorced | 1.171 | 1.088–1.259 | <0.0001 | 1.175 | 1.103–1.251 | <0.0001 |
Single (never married) | 1.332 | 1.255–1.414 | <0.0001 | 1.316 | 1.250–1.386 | <0.0001 |
Widowed | 1.376 | 1.305–1.450 | <0.0001 | 1.746 | 1.675–1.821 | <0.0001 |
Unknown | 1.045 | 0.914–1.196 | 0.5175 | 1.246 | 1.120–1.387 | 0.0001 |
CEA status | ||||||
Negative | ref | ref | ||||
Positive | 3.174 | 3.042–3.313 | <0.0001 | 2.449 | 2.366–2.535 | <0.0001 |
Tumor site | ||||||
Proximal colon | ref | ref | ||||
Distal colon | 0.892 | 0.850–0.935 | <0.0001 | 0.835 | 0.803–0.869 | <0.0001 |
Overlapping lesion of colon | 1.382 | 1.153–1.657 | 0.0005 | 1.294 | 1.108–1.510 | 0.0011 |
Rectum | 0.880 | 0.833–0.931 | <0.0001 | 0.825 | 0.787–0.865 | <0.0001 |
Tumor size | ||||||
≤ 5 cm | ref | ref | ||||
> 5 cm | 1.429 | 1.370–1.491 | <0.0001 | 1.316 | 1.270–1.363 | <0.0001 |
Unknown | 0.821 | 0.746–0.904 | 0.0001 | 0.806 | 0.745–0.873 | <0.0001 |
Extent of surgery | ||||||
Local/segmental resection | ref | ref | ||||
Subtotal/hemisection | 1.161 | 1.114–1.211 | <0.0001 | 1.181 | 1.141–1.223 | <0.0001 |
Total resection | 1.527 | 1.373–1.699 | <0.0001 | 1.388 | 1.264–1.525 | <0.0001 |
Histology | ||||||
Adenocarcinoma | ref | ref | ||||
Signet ring cell carcinoma | 2.648 | 2.304–3.044 | <0.0001 | 2.180 | 1.916–2.480 | <0.0001 |
Tumor grade | ||||||
G1/G2 | ref | ref | ||||
G3/G4 | 1.903 | 1.820–1.989 | <0.0001 | 1.614 | 1.553–1.678 | <0.0001 |
Unknown | 1.007 | 0.871–1.164 | 0.9283 | 0.942 | 0.834–1.064 | 0.3372 |
pT stage | ||||||
pT1 | ref | ref | ||||
pT2 | 1.854 | 1.556–2.209 | <0.0001 | 1.662 | 1.495–1.848 | <0.0001 |
pT3 | 6.161 | 5.285–7.182 | <0.0001 | 3.150 | 2.871–1.848 | <0.0001 |
pT4a | 13.422 | 11.43–15.760 | <0.0001 | 5.775 | 5.21–6.400 | <0.0001 |
pT4b | 17.429 | 14.844–20.464 | <0.0001 | 7.324 | 6.607–8.120 | <0.0001 |
Metastasis | ||||||
M0 | ref | ref | ||||
M1 | 7.733 | 7.414–8.066 | <0.0001 | 4.953 | 4.773–5.139 | <0.0001 |
Cancer-specific survival | Overall survival | |||||
---|---|---|---|---|---|---|
Covariates | HR | 95 % CI |
P
| HR | 95 % CI |
P
|
Sex (Male vs. Female) | 1.142 | 1.094–1.193 | <0.0001 | 1.246 | 1.202–1.293 | <0.0001 |
Race (ref, White) | ||||||
Black | 1.199 | 1.130–1.273 | <0.0001 | 1.191 | 1.132–1.254 | <0.0001 |
Yellow (Chinese, Korean, Japanese) | 0.784 | 0.702–0.875 | <0.0001 | 0.713 | 0.649–0.784 | <0.0001 |
Other | 1.030 | 0.935–1.135 | 0.5449 | 0.996 | 0.915–1.083 | 0.9203 |
Marital status at diagnosis (ref, Married) | ||||||
Divorced | 1.175 | 1.092–1.265 | <0.0001 | 1.214 | 1.139–1.293 | <0.0001 |
Single (never married) | 1.235 | 1.161–1.313 | <0.0001 | 1.277 | 1.211–1.346 | <0.0001 |
Widowed | 1.189 | 1.118–1.264 | <0.0001 | 1.224 | 1.165–1.285 | <0.0001 |
Unknown | 1.014 | 0.886–1.161 | 0.8424 | 1.145 | 1.029–1.275 | 0.0131 |
CEA status (Positive vs. negative) | 1.589 | 1.517–1.664 | <0.0001 | 1.486 | 1.431–1.543 | <0.0001 |
Extent of surgery (ref, Loc/seg resection) | ||||||
Subtotal/hemisection | 1.067 | 1.012–1.125 | 0.0156 | 1.040 | 0.995–1.087 | 0.0824 |
Total resection | 1.269 | 1.139–1.414 | <0.0001 | 1.180 | 1.073–1.297 | 0.0007 |
Tumor site (ref, Proximal colon) | ||||||
Distal colon | 0.910 | 0.860–0.962 | <0.0001 | 0.918 | 0.876–0.962 | 0.0004 |
Overlapping lesion of colon | 1.090 | 0.909–1.307 | 0.3545 | 1.111 | 0.952–1.298 | 0.1824 |
Rectum | 1.002 | 0.935–1.074 | 0.9516 | 0.981 | 0.926–1.040 | 0.5211 |
Tumor size (ref, ≤ 5 cm) | ||||||
>5 cm | 1.029 | 0.984–1.076 | 0.2050 | 1.026 | 0.989–1.066 | 0.1741 |
Unknown | 1.141 | 1.035–1.258 | 0.0078 | 1.075 | 0.991–1.166 | 0.0810 |
Histology (ref, Adenocarcinoma) | ||||||
Signet ring cell carcinoma | 1.409 | 1.220–1.626 | <0.0001 | 1.380 | 1.209–1.575 | <0.0001 |
Tumor grade (ref, G1/G2) | ||||||
G3/G4 | 1.278 | 1.219–1.339 | <0.0001 | 1.184 | 1.137–1.233 | <0.0001 |
Unknown | 1.143 | 0.987–1.323 | 0.0736 | 1.049 | 0.927–1.186 | 0.4501 |
pT stage (ref, pT1) | ||||||
pT2 | 1.567 | 1.312–1.872 | <0.0001 | 1.398 | 1.254–1.558 | <0.0001 |
pT3 | 2.949 | 2.516–3.457 | <0.0001 | 1.796 | 1.628–1.981 | <0.0001 |
pT4a | 4.429 | 3.746–5.237 | <0.0001 | 2.508 | 2.247–2.799 | <0.0001 |
pT4b | 4.760 | 4.021–5.634 | <0.0001 | 2.746 | 2.456–3.069 | <0.0001 |
Metastasis (M1 vs. M0) | 4.075 | 3.876–4.284 | <0.0001 | 3.357 | 3.213–3.508 | <0.0001 |
Nomograms for CSS and OS
Points | |||
---|---|---|---|
Variables | Labels for tick marks | CSS | OS |
Sex | |||
Female | Female | 0 | 0 |
Male | Male | 7.5 | 9.2 |
Race | |||
White | White | 13.8 | 14.1 |
Black | Black | 24.1 | 21.4 |
Yellow (Chinese, Korean and Japanese) | Yellow | 0 | 0 |
Other | Other | 15.5 | 13.9 |
Marital status at diagnosis | |||
Married (including separated) | Mar | 0 | 0 |
Divorced | Div | 9.2 | 8.1 |
Single (never married) | Sin | 11.9 | 10.2 |
Widowed | Wid | 9.8 | 8.4 |
Unknown | Uk | 0.8 | 5.7 |
CEA status | |||
Negative | Negative | 0 | 0 |
Positive | Positive | 26.2 | 16.6 |
Tumor site | |||
Proximal colon (cecum to splenic flexure) | Pc | 5.4 | 3.6 |
Distal colon (descending to sigmoid colon) | Dc | 0 | 0 |
Overlapping lesion of colon | Oc | 10.3 | 8.0 |
Rectum (including rectosigmoid junction) | Rect | 5.5 | 2.8 |
Tumor size | |||
≤5 cm | 0–5 | 0 | 0 |
>5 cm | 5+ | 1.6 | 1.1 |
Unknown | Uk | 7.5 | 3.0 |
Extent of surgery | |||
Local/segmental resection | Loc/Seg | 0 | 0 |
Subtotal/hemisection | Partial | 3.7 | 1.6 |
Total resection | Total | 13.5 | 6.9 |
Histology | |||
Adenocarcinoma | Adeno | 0 | 0 |
Signet ring cell carcinoma | Signet | 19.4 | 13.5 |
Tumor grade | |||
Well to Moderately differentiated (G1 + G2) | G1/2 | 0 | 0 |
Poorly to Undifferentiated (G3 + G4) | G3/4 | 13.9 | 7.1 |
Unknown | Uk | 7.6 | 2.0 |
pT stage | |||
pT1 | T1 | 0 | 0 |
pT2 | T2 | 25.5 | 14.0 |
pT3 | T3 | 61.3 | 24.5 |
pT4a | T4a | 84.3 | 38.4 |
pT4b | T4b | 88.4 | 42.2 |
Metastasis | |||
M0 | M0 | 0 | 0 |
M1 | M1 | 79.6 | 50.6 |
Age at diagnosis | Lymph node count, n | Lymph node ratio | ||||||
---|---|---|---|---|---|---|---|---|
Values, no. | Pts for CSS | Pts for OS | Values, no. | Pts for CSS | Pts for OS | Values, % | Pts for CSS | Pts for OS |
10 | 0.0 | 0.0 | 0 | 12.3 | 15.7 | 0 | 0.0 | 0.0 |
20 | 1.2 | 0.1 | 10 | 10.2 | 9.7 | 10 | 15.9 | 12.3 |
30 | 2.5 | 0.2 | 20 | 3.4 | 3.5 | 20 | 30.5 | 18.2 |
40 | 3.7 | 0.3 | 30 | 0.0 | 0.0 | 30 | 42.3 | 21.8 |
50 | 5.3 | 0.8 | 40 | 2.9 | 1.1 | 40 | 50.9 | 25.3 |
60 | 10.5 | 5.9 | 50 | 5.9 | 2.2 | 50 | 57.0 | 28.8 |
70 | 23.9 | 21.1 | 60 | 8.9 | 3.3 | 60 | 61.2 | 32.2 |
80 | 46.0 | 44.8 | 70 | 11.9 | 4.4 | 70 | 64.2 | 35.6 |
90 | 72.8 | 72.2 | 80 | 14.9 | 5.5 | 80 | 66.5 | 39.0 |
100 | 100.0 | 100.0 | 90 | 17.9 | 6.6 | 90 | 68.9 | 42.4 |
100 | 71.2 | 45.7 |
Internal validation
Nomogram calibration
External validation
Time-dependent ROC curve analysis
Cancer-specific survival | Overall survival | |||||||
---|---|---|---|---|---|---|---|---|
AUC, % | AUC, % | |||||||
Study cohort | 1 year | 3 years | 5 years | 7 years | 1 year | 3 years | 5 years | 7 years |
Training cohort | 85.2 | 87.6 | 87.5 | 86.6 | 82.1 | 84.1 | 84.2 | 83.6 |
Validation cohort | 83.0 | 87.1 | 86.7 | 85.5 | 80.6 | 83.7 | 83.7 | 82.7 |
Test cohort | 86.0 | 87.8 | / | / | 83.1 | 84.6 | / | / |
Comparison of nomograms with AJCC stages
Nomogram score | 7th AJCC stage | 6th AJCC stage |
P
| |
---|---|---|---|---|
Training cohort, CSS | ||||
AIC | 172262 | 174703 | 174949 | / |
Log-likelihood | −86130 | −87344 | −87468 | All <0.0001 |
C-index (95 % CI) | 0.816 (0.810–0.822) | 0.777 (0.771–0.783) | 0.774 (0.768–0.780) | All <0.0001 |
Training cohort, OS | ||||
AIC | 250348 | 255973 | 256182 | / |
Log-likelihood | −125173 | −127979 | −128085 | All <0.0001 |
C-index (95 % CI) | 0.777 (0.772–0.782) | 0.698 (0.693–0.0.703) | 0.696 (0.691–0.701) | All <0.0001 |
Validation cohort, CSS | ||||
AIC | 14983 | 15261 | 15272 | / |
Log-likelihooda | −7490 | −7623 | −7630 | All <0.0001 |
C-indexb (95 % CI) | 0.809 (0.791–0.827) | 0.770 (0.752–0.788) | 0.768 (0.750–0.786) | All <0.0001 |
Validation cohort, OS | ||||
AIC | 21611 | 22235 | 22244 | / |
Log-likelihoodc | −10805 | −11110 | −11116 | All <0.0001 |
C-indexd (95 % CI) | 0.773 (0.757–0.789) | 0.699 (0.683–0.715) | 0.697 (0.681–0.713) | All <0.0001 |
Test cohort, CSS | ||||
AIC | 102103 | 104057 | 105039 | / |
Log-likelihood | −51050 | −52021 | −52519 | All <0.0001 |
C-index (95 % CI) | 0.838 (0.830–0.846) | 0.794 (0.786–0.802) | 0.786 (0.778–0.794) | All <0.0001 |
Test cohort, OS | ||||
AIC | 141606 | 145343 | 146456 | / |
Log-likelihood | −70802 | −72664 | −73227 | All <0.0001 |
C-index (95 % CI) | 0.802 (0.796–0.808) | 0.723 (0.717–0.729) | 0.715 (0.709–0.721) | All <0.0001 |
Training cohort | Validation cohort | Test cohort | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
(Cumulative survival, 60 months, %) | (Cumulative survival, 60 months, %) | (Cumulative survival, 59 months, %) | ||||||||||
Nomo stage | CSS | 95 % CI | OS | 95 % CI | CSS | 95 % CI | OS | 95 % CI | CSS | 95 % CI | OS | 95 % CI |
Nomo 1 | 96.8 | 96.1–97.4 | 94.6 | 93.7–95.4 | 97.7 | 96.1–99.4 | 95.5 | 93.2–97.8 | 94.3 | 88.7–99.8 | 90.8 | 85.5–96.1 |
Nomo 2 | 94.0 | 93.1–95.0 | 88.1 | 86.9–89.3 | 92.9 | 90.0–95.8 | 87.1 | 83.4–90.9 | 94.0 | 91.5–96.6 | 89.0 | 86.5–91.4 |
Nomo 3 | 90.9 | 89.8–92.0 | 83.7 | 82.4–85.1 | 91.2 | 88.0–94.4 | 86.6 | 82.8–90.3 | 92.1 | 90.5–93.6 | 85.5 | 83.4–87.7 |
Nomo 4 | 87.1 | 85.8–88.4 | 76.1 | 74.5–77.7 | 88.1 | 84.4–91.7 | 78.9 | 74.4–83.4 | 87.4 | 84.5–90.3 | 76.5 | 73.5–79.5 |
Nomo 5 | 82.0 | 80.4–83.5 | 70.3 | 68.6–72.0 | 82.3 | 77.9–86.7 | 67.8 | 62.6–73.0 | 83.7 | 81.8–85.7 | 69.1 | 62.1–76.1 |
Nomo 6 | 74.2 | 72.4–75.9 | 59.0 | 57.2–60.9 | 73.6 | 68.5–78.7 | 59.4 | 54.0–64.8 | 76.1 | 73.9–78.4 | 60.1 | 56.9–63.3 |
Nomo 7 | 63.3 | 61.4–65.2 | 44.8 | 42.9–46.7 | 61.3 | 55.6–67.0 | 50.6 | 45.1–56.1 | 64.4 | 60.3–68.6 | 47.4 | 43.3–51.5 |
Nomo 8 | 43.6 | 41.6–45.6 | 32.6 | 30.9–34.4 | 50.8 | 44.8–56.8 | 32.7 | 27.5–37.9 | 49.9 | 46.9–53.0 | 31.8 | 27.9–35.7 |
Nomo 9 | 22.1 | 20.4–23.7 | 18.0 | 16.5–19.4 | 23.9 | 18.8–29.0 | 20.2 | 15.8–24.7 | 20.2 | 16.0–24.4 | 17.8 | 15.0–20.6 |
Nomo 10 | 5.7 | 4.7–6.6 | 4.8 | 4.0–5.6 | 8.4 | 5.2–11.6 | 7.3 | 4.5–10.2 | 6.3 | 3.9–8.6 | 3.8 | 1.3–6.3 |
Plog-rank for trend | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 | <0.0001 |
Training cohort | Validation cohort | Test cohort | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Nomo stages | Cut-off Points | HR | 95 % CI |
P
| HR | 95 % CI |
P
| HR | 95 % CI |
P
|
Cancer-specific survival | ||||||||||
Nomo 1 | ≤82.0 | ref | ref | ref | ||||||
Nomo 2 | ≤106.2 | 1.86 | 1.48–2.35 | <0.0001 | 2.40 | 1.19–4.84 | 0.0147 | 1.92 | 1.37–2.70 | 0.0002 |
Nomo 3 | ≤122.9 | 2.86 | 2.30–3.55 | <0.0001 | 3.33 | 1.70–6.51 | 0.0004 | 3.38 | 2.48–4.62 | <0.0001 |
Nomo 4 | ≤138.2 | 3.91 | 3.17–4.82 | <0.0001 | 4.83 | 2.54–9.22 | <0.0001 | 5.13 | 3.81–6.91 | <0.0001 |
Nomo 5 | ≤153.0 | 5.58 | 4.55–6.84 | <0.0001 | 6.60 | 3.50–12.42 | <0.0001 | 7.87 | 5.89–10.51 | <0.0001 |
Nomo 6 | ≤170.7 | 8.47 | 6.95–10.33 | <0.0001 | 10.41 | 5.60–19.32 | <0.0001 | 12.17 | 9.19–16.13 | <0.0001 |
Nomo 7 | ≤192.2 | 12.46 | 10.25–15.14 | <0.0001 | 16.23 | 8.84–29.81 | <0.0001 | 18.39 | 13.91–24.3 | <0.0001 |
Nomo 8 | ≤225.6 | 22.40 | 18.49–27.13 | <0.0001 | 21.11 | 11.53–38.67 | <0.0001 | 32.19 | 24.47–42.34 | <0.0001 |
Nomo 9 | ≤272.1 | 40.47 | 33.46–48.94 | <0.0001 | 42.87 | 23.56–78.00 | <0.0001 | 65.32 | 49.79–85.68 | <0.0001 |
Nomo 10 | 272.1+ | 83.31 | 68.9–100.73 | <0.0001 | 86.07 | 47.39–156.31 | <0.0001 | 127.46 | 97.2–167.12 | <0.0001 |
Overall survival | ||||||||||
Nomo 1 | ≤57.2 | ref | ref | ref | ||||||
Nomo 2 | ≤70.0 | 2.16 | 1.83–2.56 | <0.0001 | 1.96 | 1.19–3.22 | 0.0078 | 2.13 | 1.68–2.70 | <0.0001 |
Nomo 3 | ≤80.8 | 3.04 | 2.59–3.58 | <0.0001 | 2.63 | 1.64–4.21 | 0.0001 | 3.12 | 2.49–3.92 | <0.0001 |
Nomo 4 | ≤90.7 | 4.76 | 4.08–5.56 | <0.0001 | 4.28 | 2.73–6.71 | <0.0001 | 5.55 | 4.48–6.87 | <0.0001 |
Nomo 5 | ≤101.6 | 6.12 | 5.26–7.12 | <0.0001 | 6.17 | 3.99–9.55 | <0.0001 | 6.90 | 5.59–8.52 | <0.0001 |
Nomo 6 | ≤114.2 | 9.01 | 7.76–10.45 | <0.0001 | 8.41 | 5.47–12.92 | <0.0001 | 11.11 | 9.06–13.63 | <0.0001 |
Nomo 7 | ≤129.1 | 13.46 | 11.62–15.58 | <0.0001 | 11.25 | 7.36–17.19 | <0.0001 | 15.23 | 12.45–18.62 | <0.0001 |
Nomo 8 | ≤147.1 | 18.68 | 16.15–21.61 | <0.0001 | 16.81 | 11.04–25.61 | <0.0001 | 24.23 | 19.85–29.57 | <0.0001 |
Nomo 9 | ≤171.8 | 28.44 | 24.61–32.88 | <0.0001 | 25.47 | 16.76–38.68 | <0.0001 | 37.66 | 30.91–45.89 | <0.0001 |
Nomo 10 | 171.8+ | 55.25 | 47.8–63.86 | <0.0001 | 45.27 | 29.80–68.76 | <0.0001 | 75.07 | 61.63–91.45 | <0.0001 |
Training cohort | Test cohort | |||||||
---|---|---|---|---|---|---|---|---|
AJCC stages | Cut-off Points | Cumulative Survival, 60 months, % | HR | 95 % CI | Pairwise Plog-rank | HR | 95 % CI | Pairwise Plog-rank |
Cancer-specific survival | ||||||||
Stage I | ||||||||
Low risk group (L) | ≤70.0 | 97.7 | ref | L v M < 0.0001 | ref | L v M < 0.0205 | ||
Median risk group (M) | ≤97.2 | 94.4 | 2.44 | 1.91–3.13 | L v H < 0.0001 | 1.75 | 1.24–2.45 | L v H < 0.0001 |
High risk group (H) | 97.2+ | 88.4 | 4.73 | 3.66–6.12 | M v H < 0.0001 | 6.12 | 4.27–8.77 | M v H < 0.0001 |
Stage IIA | ||||||||
Low risk group (L) | ≤122.7 | 93.9 | ref | L v M < 0.0001 | ref | L v M < 0.0001 | ||
Median risk group (M) | ≤149.4 | 87.7 | 1.90 | 1.64–2.19 | L v H < 0.0001 | 2.11 | 1.4–2.58 | L v H < 0.0001 |
High risk group (H) | 149.4+ | 76.2 | 3.96 | 3.41–4.61 | M v H < 0.0001 | 4.66 | 3.80–5.72 | M v H < 0.0001 |
Stage IIB | ||||||||
Low risk group (L) | ≤151.2 | 84.4 | ref | L v M = 0.0046 | ref | L v M = 0.0220 | ||
Median risk group (M) | ≤178.4 | 71.1 | 1.84 | 1.28–2.64 | L v H < 0.0001 | 2.09 | 1.29–3.39 | L v H < 0.0001 |
High risk group (H) | 178.4+ | 54.1 | 3.30 | 2.22–4.90 | M v H < 0.0012 | 5.27 | 3.16–8.81 | M v H < 0.0001 |
Stage IIC | ||||||||
Low risk group (L) | ≤158.0 | 76.7 | ref | L v M = 0.0121 | ref | L v M = 0.6571 | ||
Median risk group (M) | ≤181.8 | 62.3 | 1.64 | 1.16–2.31 | L v H < 0.0001 | 1.12 | 0.72–1.74 | L v H < 0.0001 |
High risk group (H) | 181.8+ | 45.6 | 2.79 | 1.93–2.03 | M v H < 0.0020 | 2.73 | 1.68–4.42 | M v H < 0.0001 |
Stage IIIA | ||||||||
Low risk group (L) | ≤88.9 | 94.8 | ref | L v M = 0.0116 | ref | L v M < 0.0210 | ||
Median risk group (M) | ≤120.2 | 91.6 | 2.04 | 1.39–2.99 | L v H < 0.0001 | 2.51 | 1.36–4.63 | L v H < 0.0001 |
High risk group (H) | 120.2+ | 75.6 | 6.84 | 4.57–10.24 | M v H < 0.0001 | 6.54 | 3.20–13.35 | M v H = 0.0015 |
Stage IIIB | ||||||||
Low risk group (L) | ≤147.6 | 85.9 | ref | L v M < 0.0001 | ref | L v M < 0.0001 | ||
Median risk group (M) | ≤180.3 | 72.1 | 2.09 | 1.89–2.32 | L v H < 0.0001 | 2.35 | 2.04–2.70 | L v H < 0.0001 |
High risk group (H) | 180.3+ | 50.1 | 4.25 | 3.80–4.76 | M v H < 0.0001 | 5.34 | 4.55–2.67 | M v H < 0.0001 |
Stage IIIC | ||||||||
Low risk group (L) | ≤187.2 | 65.1 | ref | L v M < 0.0001 | ref | L v M < 0.0001 | ||
Median risk group (M) | ≤218.0 | 41.6 | 1.99 | 1.74–2.27 | L v H < 0.0001 | 2.01 | 1.72–2.36 | L v H < 0.0001 |
High risk group (H) | 218.0+ | 24.8 | 3.49 | 3.01–4.04 | M v H < 0.0001 | 4.05 | 3.39–4.84 | M v H < 0.0001 |
Stage IV | ||||||||
Low risk group (L) | ≤255.6 | 26.2 | ref | L v M < 0.0001 | ref | L v M < 0.0001 | ||
Median risk group (M) | ≤292.1 | 12.0 | 1.56 | 1.46–1.67 | L v H < 0.0001 | 1.85 | 1.70–2.01 | L v H < 0.0001 |
High risk group (H) | 292.1+ | 4.0 | 2.78 | 2.57–3.01 | M v H < 0.0001 | 3.34 | 3.20–3.70 | M v H < 0.0001 |
Overall survival | ||||||||
Stage I | ||||||||
Low risk group (L) | ≤55.1 | 94.6 | ref | L v M < 0.0001 | ref | L v M < 0.0001 | ||
Median risk group (M) | ≤79.9 | 84.5 | 2.94 | 2.58–3.35 | L v H < 0.0001 | 3.10 | 2.58–3.72 | L v H < 0.0001 |
High risk group (H) | 79.9+ | 63.1 | 9.07 | 7.90–10.41 | M v H < 0.0001 | 10.70 | 8.80–13.01 | M v H < 0.0001 |
Stage IIA | ||||||||
Low risk group (L) | ≤75.9 | 90.6 | ref | L v M < 0.0001 | ref | L v M < 0.0001 | ||
Median risk group (M) | ≤101.4 | 77.0 | 2.66 | 2.42–2.91 | L v H < 0.0001 | 2.86 | 2.50–3.28 | L v H < 0.0001 |
High risk group (H) | 101.4+ | 49.1 | 7.38 | 6.68–8.15 | M v H < 0.0001 | 7.80 | 6.77–8.97 | M v H < 0.0001 |
Stage IIB | ||||||||
Low risk group (L) | ≤93.5 | 80.3 | ref | L v M = 0.0007 | ref | L v M < 0.0001 | ||
Median risk group (M) | ≤120.4 | 64.7 | 1.86 | 1.40–2.45 | L v H < 0.0001 | 3.86 | 2.60–5.72 | L v H < 0.0001 |
High risk group (H) | 120.4+ | 26.8 | 5.48 | 4.00–7.49 | M v H < 0.0001 | 8.03 | 5.27–12.22 | M v H < 0.0001 |
Stage IIC | ||||||||
Low risk group (L) | ≤96.9 | 73.6 | ref | L v M < 0.0001 | ref | L v M = 0.2111 | ||
Median risk group (M) | ≤121.9 | 54.4 | 2.09 | 1.56–2.80 | L v H < 0.0001 | 1.35 | 0.92–1.98 | L v H < 0.0001 |
High risk group (H) | 121.9+ | 35.5 | 3.54 | 2.58–4.86 | M v H = 0.0002 | 3.81 | 2.46–5.91 | M v H < 0.0001 |
Stage IIIA | ||||||||
Low risk group (L) | ≤60.0 | 94.6 | ref | L v M < 0.0001 | ref | L v M < 0.0316 | ||
Median risk group (M) | ≤90.4 | 84.3 | 3.67 | 2.76–4.87 | L v H < 0.0001 | 2.10 | 1.36–3.25 | L v H < 0.0001 |
High risk group (H) | 90.4+ | 59.4 | 11.71 | 8.66–15.84 | M v H < 0.0001 | 9.07 | 5.70–14.45 | M v H < 0.0001 |
Stage IIIB | ||||||||
Low risk group (L) | ≤91.0 | 82.3 | ref | L v M < 0.0001 | ref | L v M < 0.0001 | ||
Median risk group (M) | ≤116.9 | 63.7 | 2.28 | 2.09–2.48 | L v H < 0.0001 | 2.72 | 2.42–3.07 | L v H < 0.0001 |
High risk group (H) | 116.9+ | 36.6 | 5.06 | 4.60–5.56 | M v H < 0.0001 | 6.55 | 5.75–7.47 | M v H < 0.0001 |
Stage IIIC | ||||||||
Low risk group (L) | ≤110.6 | 63.3 | ref | L v M < 0.0001 | ref | L v M < 0.0001 | ||
Median risk group (M) | ≤137.0 | 35.7 | 2.10 | 1.86–2.37 | L v H < 0.0001 | 1.94 | 1.68–2.24 | L v H < 0.0001 |
High risk group (H) | 137.0+ | 18.2 | 3.97 | 3.47–4.55 | M v H < 0.0001 | 4.33 | 3.68–5.11 | M v H < 0.0001 |
Stage IV | ||||||||
Low risk group (L) | ≤157.2 | 24.2 | ref | L v M < 0.0001 | ref | L v M < 0.0001 | ||
Median risk group (M) | ≤183.3 | 9.9 | 1.59 | 1.49–1.69 | L v H < 0.0001 | 1.87 | 1.73–2.03 | L v H < 0.0001 |
High risk group (H) | 183.3+ | 3.0 | 2.79 | 2.58–3.01 | M v H < 0.0001 | 3.51 | 3.19–3.88 | M v H < 0.0001 |